Introduction
Although ischemic stroke occurs mainly in elderly individuals aged ≥65, nowadays it is increasingly found in young individuals, even in children. According to various epidemiological studies, the incidence of stroke in subjects aged <55 ranges from 7 to 11 per 100,000 [1, 2] .
In most cases, ischemic stroke is a multifactorial disease with genetic predisposition, while the inherited risk is likely to be multigenic [3] [4] [5] . Research results suggest that the genetic predisposition might primarily influence the etiopathogenesis of premature ischemic stroke in young and middle-aged individuals [6] [7] [8] .
Recent studies have confirmed the role of the prothrombotic factor gene mutations in the development of venous thrombosis, whereas their impact on the occurrence of arterial events has not yet been clarified. The role of different prothrombotic and proatherogenic polymorphisms in the pathogenesis of ischemic stroke has been investigated [9] [10] [11] [12] [13] . Among them, the G20210A polymorphism of the prothrombin gene, the G1691A polymorphism of the factor V gene, the C677T polymorphism of the methylentetrahydrofolate reductase (MTHDR) gene and the 4G/5G polymorphism of the plasminogen activator inhibitor-1 (PAI-1) are the most frequently studied. Some studies failed, but others did demonstrate the association of these polymorphisms with the risk of ischemic stroke [6] [7] [8] [9] [10] [11] [12] . Results from these studies address the weak effect of single genetic marker on the stroke risk development; it might be stronger in younger individuals and in mutually cumulative interactions of different polymorphisms. To date, we are aware of just few studies that have investigated cumulative effect of these prothrombotic and proatherogenic polymorphisms on the stroke risk development [6, 10] .
The aim of the present study was to determine and compare the prevalence of classic vascular risk factors and polymorphisms of the G20210A coagulation factor II, Arg506Glu coagulation factor V Leiden, C677T MTHFR and 4G/5G plasminogen activator inhibitor-1 in the group of younger stroke patients and age-and sex-matched control group. In addition, the impact of these gene mutations and classic vascular risk factors on the overall stroke risk in individuals aged <55 was assessed.
Subjects and Methods
This prospective study was conducted at University Department of Neurology, Sestre milosrdnice University Hospital Center in Zagreb, Croatia, from June 2009 to January 2012.
Study protocol was consistent with ethical principles of medical profession and was approved by the Ethics committee Sestre milosrdnice University Hospital Center. All study subjects were informed on all the procedures to be used during the study and provided their written informed consent on participation in the study.
The study included 155 successive ischemic stroke patients younger than 55 and 150 age-and sex-matched control subjects. Clinical diagnosis of ischemic stroke was based on the computed tomography (CT) and magnetic resonance (MR) evidence for cerebral infarct.
Complete demographic and history data on age, sex and classic vascular risk factors for stroke, including hypertension, diabetes mellitus, cigarette smoking, hyperlipidemia and body weight were collected from both stroke patients and control subjects. Hypertension was determined on the basis of systolic blood pressure greater than 160 mm Hg or/and diastolic 5 blood pressure greater than 95 mm Hg measured at two time points at least two weeks after acute phase of ischemic stroke, or if the patient had been on antihypertensive therapy before inclusion in the study. Diabetes mellitus was diagnosed according to the World Health Organization (WHO) criteria [14] . According to smoking habits, study subjects were divided into two groups of current smokers and nonsmokers, the latter including those that had ceased smoking more than six months before. Hypercholesterolemia was defined as cholesterol levels exceeding 5 mmol/L or taking cholesterol lowering agents. Decreased HDL-cholesterol levels were defined as <1.2 mmol/L in female and <1.0 mmol/L in male subjects. Elevated LDL-cholesterol levels were defined as >3.0 mmol/L. Elevated triglyceride levels were defined as >1.7 mmol/L. Body mass index (BMI; body weight divided by square body height) was calculated in all study subjects, classifying them into three groups of normal weight (BMI Control subjects were age-and sex-matched to ischemic stroke patients, had no known history of vascular or thromboembolic disease, and had normal neurologic status. All study subjects were Caucasians, originating from the same geographical area, and were of comparable social status.
Venous blood samples were obtained from both stroke patients and control subjects for molecular diagnosis and determination of coagulation factor II, coagulation factor V, PAI-1 and MTHFR polymorphisms. All study polymorphisms were determined by the standardized polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method.
Total number of classic vascular risk factors (range 0-8) and total number of gene polymorphisms under study (range 0-4) as genetic sum were calculated in each study subject.
The normality of numerical data distribution was tested by Kolmogorov-Smirnov test.
As most of the numerical data did not follow normal distribution, nonparametric statistical tests were employed in the analysis.
Mann-Whitney test was used to compare numerical data between two independent groups of patients and control subjects. Kruskal-Wallis test was used to compare more than two independent groups of numerical data divided according to the genetic sum into five groups. In case of statistically significant difference, multiple testing of particular group pairs was performed using Mann-Whitney test with Bonferroni correction for multiple testing.
Categorical characteristics were tested by χ 2 -test whenever possible; otherwise, Fisher exact test was employed. In addition to testing the existence of associations, the strength of associations was assessed using odds ratio with the corresponding 95% confidence interval (95%CI). 
Results
The study included 305 subjects in total, i.e. 155 ischemic stroke patients and 150 control subjects. There were no statistically significant between-group age (p=0.121; MannWhitney test) and sex (p=0.778; χ 2 -test) differences.
Patient/subject distribution according to the presence of classic vascular stroke risk factors and studied polymorphisms is illustrated in Based on the final logistic model results, nonsignificant variables were excluded; these were elevated total cholesterol levels, prothrombin G20210A polymorphism, factor V Leiden
Arg506Glu polymorphism and PAI-1 4G/5G polymorphism in the (A) version, and elevated total cholesterol and obesity in the (B) version of the second multivariate logistic model. As either particular polymorphisms or genetic sum were included in the model of multivariate logistic regression, and the genetic sum proved to be superior to particular polymorphisms as a predictor, the latter was left in the final model. The MTHFR C677T polymorphism was not included in the final model due to nonsignificance of other polymorphisms making the whole of prediction system; therefore, inclusion of the genetic sum was concluded to be more useful.
Since the MTHFR C677T polymorphism plays a role in the genetic sum formation, their concurrence in the model would pose a problem of multi-colinearity and possible separation of nonsignificant predictors as significant ones with their taking over the predictive role.
The final model of logistic regression of the risk factor significance in the development of ischemic stroke included the following variables: age, decreased HDLcholesterol, hypertension, obesity, cigarette smoking, and genetic sum as a continuous variable (Table 4) . This multivariate logistic model yielded a classification accuracy of 69.8%. The model was statistically significant (p<0.001). The impact of excluded variables on the final regression model was assessed by a series of statistical testing for each individual variable, and their contribution to model modification did not exceed 20% of the statistical significance (p value). The suspicion of the possible effect of these variables was thus dissipated and there was no need to return them in the final model.
Discussion
Our study results indicated the classic vascular risk factors of elevated LDLcholesterol, cigarette smoking, hypertension, decreased HDL-cholesterol and obesity to be statistically significantly more common in the group of young and middle-aged ischemic stroke patients. A very similar profile of classic vascular risk factors in young ischemic stroke patients has also been reported elsewhere, however, differing in the order of frequency [3] [4] [5] [6] [7] [15] [16] [17] [18] [19] . These results show that conventional vascular risk factors are significant risk factors for ischemic stroke not only in the >55 age group, but also in younger population.
Like most other studies, the present study was a pair study with the candidate gene concept. A drawback of the studies employing such a methodology always lies in fear that positive associations may be apparent and negative results a consequence of inadequate statistical power.
In the present study, it was only the MTHFR C677T polymorphism that proved to be an independent risk factor for ischemic stroke in multivariate logistic regression; however, as genetic sum was superior to particular polymorphisms in predicting ischemic stroke, the MTHFR C677T polymorphism was not included in the final model due to nonsignificance of other polymorphisms constituting a unified prediction system. Other studies of the MTHFR C677T polymorphism association with ischemic stroke have produced contradictory results.
Most of the studies found mild yet statistically significant association with ischemic stroke, and it seems that the risk increase was mainly mediated by elevated homocysteine levels [10, 20] .
Multivariate logistic regression confirmed the genetic sum as a continuous variable to be a statistically significant and independent risk factor for ischemic stroke (OR 2.315; 95%CI 1.643-3.260). This result is important for confirming the hypothesis on the synergistic gene interplay. Similar analyses have rarely been reported in published studies. Pezzini et al. found that odds ratio for ischemic stroke was 1.73 with 95%CI 1.20-2.51 in subjects with one prothrombotic polymorphism and 3.00 with 95%CI 1.43-6.30 in those with two or more polymorphisms [6] .
The possibility of systematic error was obviated by double blind study protocol, so that the neurologist was blinded for the molecular diagnosis results on the study polymorphisms, whereas laboratory personnel were blinded for the rest of diagnostic work-up and classification of study subjects.
A drawback of this and other similar studies is the fact that it was a hospital based pair study. As the control group consisted of subjects treated at the same institution for other health problems, the possibility of systematic error in pair matching due to population complexity cannot be excluded. Yet, as the frequency of study polymorphisms recorded in control group corresponded to those in other groups of healthy individuals from a wider area of south-east Europe, we believe that the possible systematic error had no impact in our study.
Like most of the previous studies, our study results do not support genetic testing for susceptibility to hypercoagulability in unselected patients, but suggest its possible use and benefit in some younger age patients, primarily those where the etiology of ischemic stroke remains obscure even after comprehensive and thorough diagnostic work-up [21] [22] [23] [24] . Our study pointed to the importance and impact of genetic burden, i.e. presence of multiple gene polymorphisms in a particular patient, as an independent risk factor for overall ischemic stroke risk development. This opens the possibility of further research and use of novel preventive and therapeutic strategies in the management of ischemic stroke. 
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